Every 8-K that Atara Biotherape (ATRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ATRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATRA filings page.
Atara Biotherapeutics reported second quarter 2026 results, highlighting major cost reductions and a return to losses after a one-time revenue boost in 2025. Commercialization revenue was $0.6 million versus $17.6 million a year earlier, largely because deferred revenue was accelerated in 2025 after transferring development activities to Pierre Fabre Laboratories, leaving less to recognize in 2026. Total costs and operating expenses fell sharply to $5.4 million from $14.4 million, reflecting an 87% year-over-year reduction in costs and operating expenses and substantially lower stock-based compensation.
Atara posted a net loss of $4.8 million, or ($0.32) per share, compared with net income of $2.4 million in the prior-year quarter. Cash, cash equivalents and short-term investments were $9.9 million as of June 30, 2026, slightly above March 31, 2026. The company expects this liquidity, together with realized operating efficiencies, to fund planned operations into mid-2027. Strategically, Atara and partner Pierre Fabre had a productive FDA Type A meeting on tabelecleucel (tab-cel), are preparing a BLA resubmission using updated ALLELE trial data, and Atara is eligible for a $31 million milestone upon potential FDA approval plus double-digit tiered royalties on EBVALLO sales.
Atara Biotherapeutics, Inc. reported leadership changes in its finance organization. The company notified Chief Accounting Officer Yanina Grant-Huerta that her employment will end effective July 17, 2026. This affects oversight of financial reporting and accounting.
Effective June 26, 2026, the board appointed Kevin G. Sarney of Charles River CFO, Inc. as interim chief financial officer. He will also serve as principal financial officer and principal accounting officer under a consulting agreement with CRCFO, which can be terminated by either party with 30 days’ written notice. Mr. Sarney brings over 25 years of life science finance and accounting experience and will enter into Atara’s standard indemnification agreement for executive officers.
Atara Biotherapeutics, Inc. reported governance updates from its June 2026 shareholder meeting and a new board appointment. The board named Brian Cherry as a Class I director effective June 11, 2026, and appointed him to the Audit Committee. He will receive an initial grant of 24,000 restricted stock units vesting annually over three years, plus an annual cash retainer of $55,000 under the non‑employee director program.
Stockholders elected two directors to terms running until the 2029 annual meeting, approved on an advisory basis the compensation of named executive officers, and approved an amendment to the 2024 Equity Incentive Plan. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Atara Biotherapeutics reported first quarter 2026 results showing a sharp normalization of revenue after a one-time 2025 event and a return to modest losses. Commercialization revenue was $0.5 million, compared with $98.1 million a year earlier, when revenue was accelerated from transferring tab-cel manufacturing to Pierre Fabre.
The company posted a net loss of $4.1 million, or ($0.29) per share, versus net income of $38.0 million in the prior-year period, as operating expenses fell significantly. Research and development expenses dropped to $0.2 million and general and administrative expenses to $3.6 million, reflecting 2025 cost-reduction initiatives.
Cash, cash equivalents and short-term investments were $8.4 million as of March 31, 2026. Atara expects this balance, together with $4.8 million of at-the-market offering proceeds received after quarter end and operating efficiencies, to fund planned operations into mid-2027, despite a capital structure that includes a substantial liability related to the sale of future revenues.
Atara Biotherapeutics reported a regulatory update on tabelecleucel (tab-cel) after a recent Type A meeting with the FDA following the Complete Response Letter issued on January 9, 2026 for its Biologics License Application held by partner Pierre Fabre Pharmaceuticals.
The FDA agreed that a single-arm study using an appropriate pre-specified historical control could be considered an adequate and well-controlled study to provide safety and efficacy data for a future marketing application in relapsed or refractory EBV+ PTLD after transplant in patients two years of age and older.
Pierre Fabre plans to submit an updated dataset with additional patients and longer follow-up from the pivotal Phase 3 ALLELE study, along with supportive data, as part of a resubmission plan being defined with the FDA. Atara expects to provide a further regulatory update in the third quarter.
Atara Biotherapeutics, Inc. received a Nasdaq notice that it no longer meets the $50 million minimum market value of listed securities (MVLS) required for continued listing on the Nasdaq Global Select Market.
Nasdaq reviewed the company’s market value over the last 30 consecutive business days and found it below this threshold. Atara has until October 27, 2026 (a 180-day compliance period) to regain compliance. If its MVLS closes at or above $50 million for at least 10 consecutive business days (and potentially up to 20 days at Nasdaq’s discretion), Nasdaq will confirm renewed compliance. The company’s shares continue trading under the symbol “ATRA” while it evaluates options, which may include applying to transfer to the Nasdaq Capital Market. If compliance is not regained by the deadline, Nasdaq may move to delist the shares, a decision Atara could appeal to a Hearings Panel.
Atara Biotherapeutics reported a sharp turnaround in 2025, posting net income of $32.7 million or $2.61 per share, compared with a net loss of $85.4 million in 2024. Commercialization revenue was $120.8 million, slightly below $128.9 million a year earlier, but total costs and operating expenses fell to $84.9 million from $212.4 million as research and development and general and administrative spending were significantly reduced.
Cash, cash equivalents and short-term investments were $8.5 million as of December 31, 2025, down from $42.5 million a year earlier, yet the company expects this balance, together with $3.0 million of recent at-the-market proceeds and 2025 efficiencies, to fund operations through year-end 2026. Atara also amended its agreement with HealthCare Royalty, pushing a $9.0 million milestone payment from June 30, 2026 to January 1, 2028 in exchange for a warrant to purchase up to 400,000 shares. A Type A meeting has been scheduled for partner Pierre Fabre Pharmaceuticals and the FDA to discuss the Complete Response Letter for tabelecleucel, with a regulatory update anticipated in the second quarter.
Atara Biotherapeutics reported that the U.S. Food and Drug Administration has granted a Type A meeting to discuss the Complete Response Letter for the EBVALLO™ Biologics License Application for tabelecleucel (tab-cel), which is held by its partner Pierre Fabre Pharmaceuticals. Atara will support Pierre Fabre in addressing FDA feedback using additional efficacy data collected since the original submission to enable a resubmission. The company stated it anticipates providing a further regulatory update in the second quarter.
Atara Biotherapeutics reported that its partner Pierre Fabre Pharmaceuticals has requested a Type A meeting with the U.S. Food and Drug Administration to discuss tabelecleucel (tab-cel). The meeting request follows the Complete Response Letter for the EBVALLO™ Biologics License Application dated January 9, 2026.
Atara states that a briefing book was submitted to the FDA addressing points in the letter, including arguments that the ALLELE study was adequate, well-controlled, and sufficient to support the application. The briefing materials also summarize updated longer-term efficacy data from ALLELE, additional supportive data from the development program, and post-marketing data in Europe that may be used in a potential resubmission.
Atara Biotherapeutics has amended its royalty purchase agreement with HealthCare Royalty (HCRx), pushing back a one-time $9.0 million milestone payment from June 30, 2026 to January 1, 2028. This later due date eases near-term cash obligations tied to its commercialization agreement with Pierre Fabre Medicament.
In return, Atara issued HCRx a warrant to purchase up to 400,000 shares of common stock at an exercise price of $0.0001 per share. The warrant is immediately exercisable, has no expiration date, and includes a 4.99% beneficial ownership cap, with the option for cashless exercise. Atara plans to register the resale of the underlying shares in a future registration statement.
Atara Biotherapeutics, Inc. filed a current report describing two developments. The company provided a preliminary estimate of its cash, cash equivalents and short-term investments as of December 31, 2025, explaining that this early figure does not include all information needed to fully understand its year-end financial condition or fourth-quarter results.
Atara also reported that the U.S. Food and Drug Administration issued a Complete Response Letter for the Biologics License Application for EBVALLO™ (tabelecleucel). This means the application was not approved in its current form and further action would be required before EBVALLO could be considered again for U.S. approval. The company disclosed this regulatory and business update via a press release attached as an exhibit.
Atara Biotherapeutics furnished a current report announcing its financial results and operational progress for the quarter ended September 30, 2025. The details are provided in a press release titled “Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress,” included as Exhibit 99.1.
The company states this information is furnished, not filed, and is therefore not subject to Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act, unless specifically incorporated by reference. Atara’s common stock trades on Nasdaq under the symbol ATRA.
Atara Biotherapeutics, Inc. reported a significant workforce reduction, cutting approximately 29% of its current employees and retaining about 15 employees who are considered essential to its strategic priorities. The reduction in force is expected to be completed by January 2026.
The company expects to recognize about $1.3 million in severance and related benefits tied to this action. Approximately half of these charges relate to salary continuation and wages for the 60-day notice period required under the California Worker Adjustment and Retraining Notification Act. The company notes that it may incur additional charges or cash expenditures related to this workforce reduction, with further details to be provided in its Quarterly Report on Form 10-Q for the period ending September 30, 2025.
Atara Biotherapeutics reported that it announced financial results for the second quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1 to its Form 8-K. The filing specifies the press release is being furnished (not "filed") and therefore is not subject to the liabilities of Sections 11 and 12(a)(2) of the Securities Act or deemed "filed" under Section 18 of the Exchange Act, and will not be incorporated by reference into other SEC filings unless expressly referenced. The Form lists the company ticker as ATRA and is signed by the Chief Accounting Officer.